IBCSG 16-98 / BIG 2-97

  • Exemestane vs. tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years

  • Study Chairs
    Dr. Hervé Bonnefoi - Genève, Switzerland
    Prof. Alan Coates - Centennial Park, Australia

    Director of the Data Management Center
    Holly Shaw

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


    Date of Activation
    May 1998

    Date of Closure
    August 31, 2001

    Targeted Accrual
    4400 patients

    Final Accrual
    4742 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login